Key result
DC cardioversion after PMBV shows no benefit over rate control for early atrial function.
Why the study?
Does DC cardioversion after amiodarone infusion improve echocardiographic atrial functions compared to rate control in patients with mitral stenosis and AF post-PMBV?
RCT (n=34)
Does DC cardioversion after amiodarone infusion improve echocardiographic atrial functions compared to rate control in patients with mitral stenosis and AF post-PMBV?
Early cardioversion of atrial fibrillation within 24 hours after percutaneous mitral balloon valvuloplasty does not provide additional improvement in echocardiographic atrial functions at 48-72 hours compared to rate control.
Does not support routine DC cardioversion for atrial function recovery after valvuloplasty; leaves open optimal rhythm strategies in mitral stenosis.
Amongst patients with mitral stenosis (MS), the most common complication is AF.Our study aimed at evaluating the effect of AF cardioversion after Percutaneous Mitral Balloon Valvuloplasty (PMBV) on echocardiographic atrial functions. The study included 34 patients with MS and AF, presenting to Ain-shams University hospitals, who underwent successful PMBV then randomized into 2 different groups according to AF management strategy. Group-I patients (n=16) received DC cardioversion after amiodarone infusion (within 24 hours post-PMBV) in addition to anticoagulation. Group-II patients (n= 18) were kept on the rate control strategy for AF and anticoagulation. Atrial functions were evaluated by echocardiography before and 48-72 hours after PMBV. Both groups were homogenous regarding demographic, clinical and echocardiographic data before PMBV. Both groups showed significant improvement in MVA (Group-I: 0.953 ± 0.144cm2 to 2.26 ± 0.463cm2, p=0.000, Group-II: 0.942 ± 0.171cm2 to 1.95 ± 0.40cm2 , p=0.0000), left atrial emptying fraction (Group-I:16.11 ± 6.93% to 26.16 ± 5.51%, p=0.000 , Group-II: 18.49 ± 5.47% to 26.12 ± 7.68%, p=0.002), left atrial function index (Group-I: 4.48 ± 2.32 to 6.84 ± 3.35, p=0.001 , Group-II: 3.34 ± 1.42 to 7.80 ± 4.17, p=0.006) as well as estimated systolic pulmonary artery pressure (Group-I: 49.06 ± 13.86 to 38.25 ± 7.29, p=0.01 , Group-II: 53.44 ± 14.52 to 39.88 ± 10.67, p=0.003). For group-I patients, reduction in left atrial end-diastolic volume was significant (120.84 ± 32.82 mL to 95.31 ± 19.27mL, p=0.012) and TAPSE showed significant improvement (17.57± 4.96 to 21.08 ± 2.52,p=0.018). When percentage improvement in variables was compared between both groups, none of the indices used to evaluate atrial functions showed any significant difference between both groups. Atrial functions improve post-PMBV. No additional improvement in atrial functions occurs after cardioversion in patients who have already undergone PMBV, at least within 72-hours.
No takes yet. Share an insight, caveat, or question.
Morttada et al. (2016) conducted an RCT in Mitral stenosis and atrial fibrillation (n=34). DC cardioversion after amiodarone infusion vs. Rate control strategy was evaluated on Percentage improvement in echocardiographic atrial functions. DC cardioversion after percutaneous mitral balloon valvuloplasty did not significantly improve echocardiographic atrial functions compared to rate control within 72 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: